Jefferies Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Jefferies Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-162,300	Closed	-$20.1M	–	2796
2019 Q4	$20.1M	Buy	162,300 +58,200	+56%	+$5.21M	0.16%	112
2019 Q3	$6.91M	Buy	+104,100	New	+$6.99M	0.05%	359
2019 Q2	–	Sell	-1,000	Closed	-$112K	–	2955
2019 Q1	$112K	Sell	1,000 -18,400	-95%	-$2.01M	﹤0.01%	2092
2018 Q4	$1.96M	Buy	+19,400	New	+$2.01M	0.02%	836
2017 Q4	–	Sell	-90,000	Closed	-$5.22M	–	2887
2017 Q3	$5.22M	Buy	+90,000	New	+$9.69M	0.03%	513
2017 Q1	–	Sell	-4,000	Closed	-$435K	–	2723
2016 Q4	$435K	Hold	4,000	–	–	﹤0.01%	1641
2016 Q3	$658K	Buy	+4,000	New	+$631K	﹤0.01%	1496
2016 Q2	–	Sell	-38,100	Closed	-$4.89M	–	2516
2016 Q1	$4.89M	Buy	+38,100	New	+$4.5M	0.03%	490
2015 Q1	–	Sell	-4,000	Closed	-$624K	–	2462
2014 Q4	$624K	Buy	+4,000	New	+$739K	﹤0.01%	1180
2014 Q3	–	Sell	-10,000	Closed	-$2.37M	–	2525
2014 Q2	$2.37M	Buy	+10,000	New	+$2.64M	0.02%	576

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jefferies Group's ICPT Position: Q1 2021 in Review

Jefferies Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2021, closing a stake of 22,406 shares — an estimated $553K sold.

Jefferies Group first reported a position in ICPT in Q2 2014 and held it in 20 quarters. The position peaked at $15M in Q3 2017. 151 funds tracked by Wall St. Rank hold ICPT as of Q1 2021.

Jefferies Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 22,406 Intercept Pharmaceuticals, Inc. shares in Q1 2021, an estimated $553K.
Jefferies Group first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 20 quarters.
Jefferies Group's Intercept Pharmaceuticals, Inc. position peaked at $15M in Q3 2017.
151 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.